Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | USP5 | P45974 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MMP12 | P39900 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5717808 | 0.95 | KMT2A (0.63) | SMN1; SMN2CYP1A2FFAR1LMNARAB9A | |
| SCHEMBL10884944 | 0.85 | SMN1; SMN2 (0.88) | SMN1; SMN2CYP1A2FFAR1LMNARAB9A | |
| SCHEMBL7575160 | 0.84 | NR4A2 (0.59) | SMN1; SMN2CYP1A2FFAR1LMNARAB9A | |
| SCHEMBL7862894 | 0.81 | HAO1 (0.50) | SMN1; SMN2CYP1A2FFAR1LMNARAB9A | |
| SCHEMBL7862896 | 0.81 | HAO1 (0.50) | SMN1; SMN2CYP1A2FFAR1LMNARAB9A | |
| SCHEMBL7857467 | 0.80 | KMT2A (0.89) | SMN1; SMN2CYP1A2FFAR1LMNARAB9A | |
| SCHEMBL461531 | 0.80 | HAO1 (0.51) | SMN1; SMN2CYP1A2LMNARAB9AHAO1 | |
| Fenbufen SCHEMBL25117 | 0.80 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP1A2FFAR1LMNARAB9A | |
| SCHEMBL10884661 | 0.80 | NR4A2 (0.63) | SMN1; SMN2CYP1A2FFAR1LMNARAB9A | |
| Fenbufen SCHEMBL11329267 | 0.80 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP1A2FFAR1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6307089-B2 | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY | 2001-10-23 | — | — | US | disclosed |
| US-6239288-B1 | RHEUMATIC DISEASES | WARNER-LAMBERT COMPANY | 2001-05-29 | — | — | US | disclosed |
| US-20010000513-A1 | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY | 2001-04-26 | — | — | US | disclosed |
| EP-0927156-A1 | BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998009940-A1 | BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010000513-A1 | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases | MMP26, MMP1, MMP9 | SMN1; SMN2 1912/4885CYP1A2 1694/4885FFAR1 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.